^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunosuppressant

    Related drugs:
    20h
    PROMISE-MG: Disease-Modifying Treatments for Myasthenia Gravis (clinicaltrials.gov)
    P=N/A, N=82, Completed, Duke University | N=167 --> 82
    Enrollment change • HEOR
    24h
    LAMB-SOT: Liposomal Amphotericin B for Invasive Fungal Disease in Solid Organ Transplant Recipients (clinicaltrials.gov)
    P=N/A, N=120, Not yet recruiting, Sichuan Provincial People's Hospital
    New trial • Real-world evidence
    1d
    INSTEAD: Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies (clinicaltrials.gov)
    P3, N=244, Recruiting, University Hospital, Tours | Trial completion date: Mar 2030 --> Dec 2030 | Trial primary completion date: Mar 2027 --> Dec 2030 | Not yet recruiting --> Recruiting
    Enrollment open • Trial completion date • Trial primary completion date
    4d
    Disseminated Tuberculosis With Placental Involvement in a Crohn's Disease Patient Treated With Combination Therapy. (PubMed, Gastro Hep Adv)
    We report the case of a 39-year-old pregnant woman with ileal Crohn's disease who developed severe, life-threatening disseminated tuberculosis during treatment with infliximab and azathioprine. The case highlights the possibility of involvement of atypical sites, such as the placenta. In endemic areas, a high index of suspicion is required for uncommon manifestations of the disease.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    10d
    TEMPO-LT: TLI- and ATG-Enabled Minimization Protocol in Liver Transplantation (clinicaltrials.gov)
    P1/2, N=12, Not yet recruiting, Stanford University
    New P1/2 trial
    10d
    Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Stanford University
    New P2 trial
    |
    TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • MECOM (MDS1 And EVI1 Complex Locus) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV
    10d
    Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction (clinicaltrials.gov)
    P4, N=48, Recruiting, University of Alabama at Birmingham | Not yet recruiting --> Recruiting
    Enrollment open
    11d
    THYMO B: Influence of Thymoglobuline on Phenotypic and Functional Profiles of B Lymphocytes in Renal Transplant Recipients (clinicaltrials.gov)
    P=N/A, N=49, Completed, University Hospital, Brest | Unknown status --> Completed
    Trial completion
    11d
    Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy (clinicaltrials.gov)
    P1, N=24, Enrolling by invitation, Stanford University | Trial completion date: May 2028 --> Dec 2030 | Trial primary completion date: May 2025 --> Dec 2030 | Not yet recruiting --> Enrolling by invitation
    Enrollment open • Trial completion date • Trial primary completion date
    16d
    MYCOHYPE: An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis (clinicaltrials.gov)
    P4, N=144, Active, not recruiting, Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    prednisolone
    16d
    D3461C00040: A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-nave and Biologic-nave Systemic Lupus Erythematosus (2025-523670-17-00)
    P2/3, N=55, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    16d
    CSAGCD: Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks (clinicaltrials.gov)
    P4, N=60, Not yet recruiting, Baylor College of Medicine | Initiation date: Apr 2026 --> Sep 2026
    Trial initiation date